EUSA Pharma Adds Carsten Thiel and Darrel P. Cohen into its Senior Leadership Team

EUSA Pharma (EUSA), a world’s leading Biopharmaceutical Company that specializes in oncology and uncommondisease, on May 15, 2019, announced reorganizations of its senior leadership team with the inclusion of top minds in the pharmaceutical industry. Carsten Thiel joins EUSA as the President Europe while Darrel P. Cohen will be in charge of clinical development. Armed with their extensive pharmaceutical experience, these two executives will steer EUSA’s rapidly expanding commercial infrastructure in Europe as well as global late-stage clinical development endeavors.

Dr. Carsten Thiel in Brief

Dr. Carsten Thiel brings unrivaled commercial experience of 27 years acquired in a wide array of senior positions in the pharmaceutical sector. He was recently working at Abeona Therapeutics Inc., a U.S.-based company focused on gene therapy, as the CEO. Before this, Dr. Thiel was serving as a chief commercial officer at Alexion Pharmaceuticals, a company that specializes in rare diseases. He will be remembered for overseeing the company’s Asia Pacific, EMEA, and Australia branches. After steering Amgen’s European oncology franchise into success, the company appointed him as the head of Europe. At the onset of his pharmaceutical career, Dr. Thiel was working at Hoffman La-Roche. He acquired his doctorate degree in Molecular Biology and Biochemistry from Germany-headquartered Max Planck Institute.

Dr. Darrel P. Cohen

Dr. Cohen is a respected hematologist/oncologist with unparalleled experience in clinical development spanning two decades. Most recently, he was the VP in charge of clinical development at Pfizer, an internationally known oncology organization. Here, he oversaw clinical development for a couple of effective products like SUTENT® and XALKORI®. Before this, he was a senior director at Sanofi-Aventis Oncology responsible for clinical research. He worked at the revered Duke University Medical Center as the Hematology/Oncology Fellow before being appointed as an Associate in Medicine.

EUSA Pharma

Since its establishment in March 2015, EUSA Pharma has transformed into a global authority when it comes to oncology and rare diseases. The biopharmaceutical company has a strong presence in the U.S. and Europe as well as other markets throughout the world. It has a competent management team armed with extensive pharmaceutical experience and strong financial muscle thanks to the funding it gets from EW Healthcare Partners.

Learn more about Carsten : https://investors.karyopharm.com/news-releases/news-release-details/karyopharm-appoints-carsten-thiel-phd-its-board-directors